Table of Contents

ZYMOGENETICS INC filed this Form 10-K on March 1, 2010.

Click on link to view section or document

Entire Document w/ attachment(s)

Entire Document (10-K) PAGE 1. UNITED STATES PAGE 2. ZYMOGENETICS, INC. PAGE 3. PART I PAGE 4. IL-31 mAb. PAGE 5. (1) PAGE 6. N/A PAGE 7. Clinical Trials. PAGE 8. Product Candidates PAGE 9. N/A PAGE 10. in vivo PAGE 11. Metastatic Renal Cell Carcinoma. PAGE 12. Out-licensed Product Candidates PAGE 13. Other Out-licensed Product Candidates PAGE 14. Out-licensed Commercial Products PAGE 15. Commercialization PAGE 16. Manufacturing PAGE 17. Manufacturing Changes PAGE 18. Bayer License and Collaboration Agreement for rThrombin and U.S. Co-Promotion Agreement for RECOTHRO PAGE 19. Novo Nordisk License Agreements for IL-21 PAGE 20. Merck Serono Strategic Alliance Agreement PAGE 21. Commercial Product/Product Candidate PAGE 22. Government Regulation PAGE 23. N/A PAGE 24. Competition PAGE 25. N/A PAGE 26. N/A PAGE 27. If we fail to obtain or generate the capital we need to fund our operations, we will be unable to co PAGE 28. We are subject to extensive and rigorous governmental regulation including the requirement of approv PAGE 29. N/A PAGE 30. Our success with RECOTHROM will depend on our ability to effectively compete with large and well est PAGE 31. N/A PAGE 32. N/A PAGE 33. Pending litigation by our primary competitor for RECOTHROM could have an adverse impact on our busin PAGE 34. N/A PAGE 35. inter-partes PAGE 36. We may be unable to protect our unpatented proprietary technology and information. PAGE 37. We rely on contract suppliers to manufacture commercial supplies of RECOTHROM and clinical material PAGE 38. We may be unable to generate any revenue from product candidates developed by collaborators or licen PAGE 39. RECOTHROM has not been approved for sale outside of the United States and Canada and we intend to se PAGE 40. Because we will depend on third parties to conduct certain laboratory tests, clinical trials and oth PAGE 41. Our restructuring activities in 2009 may place a strain on certain of our remaining personnel, and m PAGE 42. We are exposed to financial risks related to foreign currency exchange rates. PAGE 43. Negative public opinion and increased regulatory scrutiny of genetic and clinical research may limit PAGE 44. Risks Related to Ownership of Our Stock PAGE 45. N/A PAGE 46. We may become involved in securities class action litigation that could divert management’s attentio PAGE 47. Item 3. Legal Proceedings PAGE 48. PART II PAGE 49. 1/1/05 PAGE 50. Item 6. Selected Financial Data PAGE 51. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations PAGE 52. Results of Operations PAGE 53. N/A PAGE 54. Costs and expenses PAGE 55. 2009 PAGE 56. Selling, general and administrative. PAGE 57. Other Income (Expense) PAGE 58. Cash flows from operating activities PAGE 59. Cash flows from investing activities PAGE 60. Contractual Obligations PAGE 61. Inventory obsolescence PAGE 62. Item 7A. Qualitative and Quantitative Disclosures About Market Risk PAGE 63. Item 8. Financial Statements and Supplementary Data PAGE 64. REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PAGE 65. ZYMOGENETICS, INC. PAGE 66. N/A PAGE 67. N/A PAGE 68. N/A PAGE 69. N/A PAGE 70. N/A PAGE 71. N/A PAGE 72. N/A PAGE 73. N/A PAGE 74. N/A PAGE 75. N/A PAGE 76. N/A PAGE 77. N/A PAGE 78. N/A PAGE 79. N/A PAGE 80. N/A PAGE 81. N/A PAGE 82. N/A PAGE 83. N/A PAGE 84. N/A PAGE 85. N/A PAGE 86. N/A PAGE 87. N/A PAGE 88. N/A PAGE 89. N/A PAGE 90. N/A PAGE 91. N/A PAGE 92. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure PAGE 93. Item 9B. Other Information PAGE 94. Equity Compensation Plan Information PAGE 95. PART IV PAGE 96. Exhibit PAGE 97. N/A PAGE 98. N/A PAGE 99. N/A PAGE 100. SIGNATURES

Entire Document (EX-10.15) PAGE 1. Exhibit 10.15 PAGE 2. 1.12 PAGE 3. 4. Term; Termination PAGE 4. 4.6 Survival PAGE 5. Annual Performance Bonus PAGE 6. 7. Termination Payments PAGE 7. 7.3 Termination Other than for Cause or for Good Reason During Change in Control Period PAGE 8. N/A PAGE 9. 7.7 Change in Control PAGE 10. Board Change PAGE 11. 7.9 Parachute Payments. PAGE 12. 7.10 Withholding PAGE 13. 9. General Release of Claims and Compliance by Executive PAGE 14. 11. Notice and Cure of Breach PAGE 15. 16. Amendments in Writing PAGE 16. 19. Governing Law PAGE 17. 22. Multiple Copies

Entire Document (EX-10.16) PAGE 1. Exhibit 10.16 PAGE 2. 1.9 PAGE 3. 3. Duties PAGE 4. 4.5 Termination Date PAGE 5. 5.4 Other Benefits PAGE 6. 6. Expenses PAGE 7. 7.2 Termination Other than for Cause or for Good Reason NOT During Change in Control Period PAGE 8. 7.4 Termination as a Result of Death or Total Disability PAGE 9. 7.6 Cause PAGE 10. Business Combination PAGE 11. N/A PAGE 12. Tax Advisor PAGE 13. 8.2 Waiver of Non-competition PAGE 14. 10. Return of Materials PAGE 15. 14. Waiver PAGE 16. 18. Entire Agreement PAGE 17. 22. Multiple Copies

Entire Document (EX-10.17) PAGE 1. Exhibit 10.17 PAGE 2. 1.9 PAGE 3. 3. Duties PAGE 4. 4.5 Termination Date PAGE 5. 5.4 Other Benefits PAGE 6. 6. Expenses PAGE 7. 7.2 Termination Other than for Cause or for Good Reason NOT During Change in Control Period PAGE 8. 7.4 Termination as a Result of Death or Total Disability PAGE 9. 7.6 Cause PAGE 10. Business Combination PAGE 11. N/A PAGE 12. Tax Advisor PAGE 13. 8.2 Waiver of Non-competition PAGE 14. 10. Return of Materials PAGE 15. 14. Waiver PAGE 16. 18. Entire Agreement PAGE 17. 22. Multiple Copies

Entire Document (EX-10.18) PAGE 1. Exhibit 10.18 PAGE 2. 1.9 PAGE 3. 3. Duties PAGE 4. 4.4 Notice of Termination PAGE 5. 5.4 Other Benefits PAGE 6. 6. Expenses PAGE 7. 7.2 Termination Other than for Cause or for Good Reason NOT During Change in Control Period PAGE 8. 7.4 Termination as a Result of Death or Total Disability PAGE 9. 7.6 Cause PAGE 10. Business Combination PAGE 11. 7.9 Parachute Payments. PAGE 12. Tax Advisor PAGE 13. 8.2 Waiver of Non-competition PAGE 14. 10. Return of Materials PAGE 15. 14. Waiver PAGE 16. 18. Entire Agreement PAGE 17. 22. Multiple Copies

Entire Document (EX-10.37) PAGE 1. Exhibit 10.37 PAGE 2. CONTENTS PAGE 3. N/A PAGE 4. N/A PAGE 5. N/A PAGE 6. THIRD RESTATED LICENSE AGREEMENT PAGE 7. 1.1.2 PAGE 8. 1.1.13 PAGE 9. 1.1.24 PAGE 10. Appendix 1. PAGE 11. 1.1.35 PAGE 12. Combination Product PAGE 13. Section 1.1.45(a) PAGE 14. 1.1.54 PAGE 15. 1.1.60 PAGE 16. clause (b) PAGE 17. 2.4 PAGE 18. 2.7 PAGE 19. Appendix 6. PAGE 20. 3.3 PAGE 21. 4.2 PAGE 22. 4.4.2 Royalties under [*] Agreement PAGE 23. Section 4.4.1 PAGE 24. 4.9 PAGE 25. Aggregate Net Sales in Territory PAGE 26. N/A PAGE 27. 5.5 PAGE 28. 5.6 PAGE 29. Article 6 PAGE 30. Long-Range Plan PAGE 31. 6.4 PAGE 32. 7.2 PAGE 33. ARTICLE EIGHT PAGE 34. ARTICLE NINE PAGE 35. 02-11 PAGE 36. Section 9.2(c) PAGE 37. 9.5 PAGE 38. 9.6 PAGE 39. 9.9 PAGE 40. 10.3 PAGE 41. Section 10.5 PAGE 42. Section 10.9(a) PAGE 43. 11.2 PAGE 44. 11.3 PAGE 45. 12.2 PAGE 46. 12.4 PAGE 47. 12.9 PAGE 48. 12.13 PAGE 49. NOVO NORDISK A/S PAGE 50. [*] PAGE 51. SCHEDULE 2 PAGE 52. IL-21 mAb PAGE 53. possibility that clinical trials involving IL-21 mAb reveal that it is not effective or has undesir PAGE 54. [*] PAGE 55. N/A PAGE 56. N/A PAGE 57. N/A PAGE 58. N/A PAGE 59. APPENDIX 4 PAGE 60. N/A PAGE 61. [*] PAGE 62. N/A

Entire Document (EX-10.41) PAGE 1. Exhibit 10.41 PAGE 2. N/A PAGE 3. N/A PAGE 4. N/A

Entire Document (EX-10.43) PAGE 1. Exhibit 10.43 PAGE 2. 3.5 Manufacturing Process PAGE 3. Milestone Payment PAGE 4. N/A PAGE 5. N/A PAGE 6. N/A

Entire Document (EX-10.45) PAGE 1. Exhibit 10.45 PAGE 2. BORROWER:

Entire Document (EX-10.46) PAGE 1. Exhibit 10.46 PAGE 2. Section 4.2 Conditions to Disbursements Made after January 26, 2010 PAGE 3. IN WITNESS WHEREOF

Entire Document (EX-23.1) PAGE 1. Exhibit 23.1

Entire Document (EX-31.1) PAGE 1. Exhibit 31.1

Entire Document (EX-31.2) PAGE 1. Exhibit 31.2

Entire Document (EX-32.1) PAGE 1. Exhibit 32.1